Compare CLW & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLW | SLGL |
|---|---|---|
| Founded | 1926 | 1997 |
| Country | United States | Israel |
| Employees | 3710 | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.1M | 254.1M |
| IPO Year | 2008 | 2016 |
| Metric | CLW | SLGL |
|---|---|---|
| Price | $20.33 | $68.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $20.33 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 122.9K | 56.4K |
| Earning Date | 04-28-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,555,400,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.16 | $223.84 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.42 | N/A |
| 52 Week Low | $11.73 | $23.15 |
| 52 Week High | $23.59 | $97.97 |
| Indicator | CLW | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 47.70 | 37.83 |
| Support Level | $20.28 | $64.78 |
| Resistance Level | $20.80 | $80.66 |
| Average True Range (ATR) | 0.86 | 4.42 |
| MACD | -0.26 | -0.93 |
| Stochastic Oscillator | 46.65 | 15.21 |
Clearwater Paper Corp is engaged in the manufacturing and supplier of Solid Bleached Sulfate (SBS) paperboard packaging products. The company products includes: SBS paperboard which is a premium paperboard grade that is frequently used to produce folding cartons, food service, commercial printing items. It generates maximum revenue from Pulp and Paperboard segment. Company operate in United States and have globalized access too. Geographically, it derives maximum revenue from the United States.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.